No profile data available.
BioMarin Pharmaceutical Inc. (BMRN) is a healthcare company in the metabolic process treatment drugs industry, based in San Rafael, United States, with about 3,221 full-time employees.
It reported revenue of $3.22 billion for fiscal year 2025, up 12.9% from fiscal year 2024, and net income of $348.90 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $989.71 million, up 19.9% from a year before. United States was its largest region in fiscal year 2025, with 37% of revenue. Its market capitalization was $10.61 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BioMarin Pharmaceutical reported $3.22 billion in revenue for fiscal year 2025, up 12.9% from $2.85 billion in fiscal year 2024. In Q2 2026 revenue was $989.71 million.
United States: 37% of revenue by region in fiscal year 2025, followed by Europe (30%).
$10.61 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Disc Medicine, Inc. (IRON), NewAmsterdam Pharma Company N.v. (NAMS), Maze Therapeutics, Inc. (MAZE), Zevra Therapeutics, Inc. (ZVRA).